Intellia Therapeutics NTLA Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's deferred revenue?
- Intellia Therapeutics (NTLA) reported deferred revenue of $630K in Q1 2026.
- How has Intellia Therapeutics's deferred revenue changed year-over-year?
- Intellia Therapeutics's deferred revenue decreased by 97.0% year-over-year, from $20.66M to $630K.
- What is the long-term trend for Intellia Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), Intellia Therapeutics's deferred revenue has grown at a -20.2% compound annual growth rate (CAGR), from $22.54M to $7.29M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.